What they were paid
PUMA BIOTECHNOLOGY Director Compensation Table · all 2 fiscal years held| Fiscal year | Cash fees | Stock awards | Option awards | Other | Total |
|---|---|---|---|---|---|
| FY2025 | $70,000 | $95,580 | $0 | $0 | $165,580 |
| FY2024 | $70,000 | $83,430 | — | — | $153,430 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: PUMA BIOTECHNOLOGY, INC. DEF 14A filed April 28, 2026, accession 0001437749-26-013671, and prior-year filings. Open the filing on EDGAR.
How this board is paid
company policy · FY2025PUMA BIOTECHNOLOGY pays directors a $50,000 cash retainer and $95,580 in equity.
Committees
FY2025 · as the proxy prints themNominating/Governance · Research and Development (Chair)
The rest of the PUMA BIOTECHNOLOGY board
FY2025 · as the company reported each| Director | Role | FY2025 total |
|---|---|---|
| Alan H. Auerbach | Chair of the Board | $0 |
| Alessandra Cesano, M.D., Ph.D | Independent Director | $153,080 |
| Allison Dorval | Independent Director | $155,580 |
| Brian Stuglik, R.Ph | Independent Director | $168,080 |
| Jay M. Moyes | Lead Independent Director | $173,080 |
| Michael P. Miller | Independent Director | $158,080 |
| Troy E. Wilson, Ph.D., J.D | Independent Director | $173,080 |
The full PUMA BIOTECHNOLOGY compensation record
free company briefThis page is one director within PUMA BIOTECHNOLOGY's record. The company brief lists every named executive and director, each linking to their own page.
Velarion Pro: every company page, peer tools and exports, one seat